Anti–vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD) is associated with increased risk of endophthalmitis, uveitis, and vitreous hemorrhage, according to a recent study. Since 2005, the advent and widespread use of anti–vascular endothelial growth factor (VEGF) drugs for the...

Avastin (bevacizumab) is the most popular pharmacological treatment for neovascular age-related macular degeneration (AMD) among Medicare fee-for-service beneficiaries in the United States. Over the past 3 years, both Avastin (bevacizumab) and Lucentis (ranibizumab) have emerged as the most common therapies for neovascular AMD as reported by...

Although Medicare has covered low-vision services performed by an ophthalmologist, optometrist, or occupational therapist since 2002, the number of service providers is limited, leaving many people without needed help. The Low Vision Demonstration Project offers some relief by expanding Medicare's coverage to include services provided by...